Fertility and Sterility
Volume 91, Issue 6 , Pages 2616-2619, June 2009

Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels

  • Tomer Singer, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Lenox Hill Hospital, New York, NY
    • The Center for Human Reproduction, New York, NY
    • ,
  • David H. Barad, M.D., M.S.

      Affiliations

    • The Center for Human Reproduction, New York, NY
    • Corresponding Author InformationReprint requests: David H. Barad, M.D., M.S., The Center for Human Reproduction, 21 East 69th Street, New York, NY 10021 (FAX: 212-994 4499).
    • ,
  • Andrea Weghofer, M.D., Ph.D.

      Affiliations

    • The Center for Human Reproduction, New York, NY
    • Department of Obstetrics and Gynecology, Allgemeine Krankenhaus, Vienna University School of Medicine, Vienna, Austria
    • ,
  • Norbert Gleicher, M.D.

      Affiliations

    • The Center for Human Reproduction, New York, NY

Received 13 February 2008; received in revised form 12 March 2008; accepted 13 March 2008. published online 13 June 2008.

Objective

To compare how a given level of antimüllerian hormone (AMH) might be used to predict the level of FSH.

Design

Retrospective cohort study.

Setting

Academically affiliated private fertility center.

Patient(s)

Eighty-one women in preparation for an IVF cycle.

Intervention(s)

None.

Main Outcome Measure(s)

Levels of FSH and AMH before start of ovulation induction.

Result(s)

Serum AMH and log-converted FSH levels were negatively correlated (R2 = 0.42). The linear regression model for FSH, based on random AMH, was as follows: LnFSH = 2.3 + −0.25 × lnAMH; 95% confidence limits of the coefficient 0.-32 to 0.-18, suggesting that an AMH level of 0.5 ng/mL is predictive of a baseline FSH level of 12.1 mIU/mL (95% confidence interval 11.4–12.7 mIU/mL).

Conclusion(s)

These data demonstrate a statistical association between FSH and AMH in assessing ovarian reserve. Using FSH and AMH in combination may improve the evaluation of ovarian reserve. However, it remains to be determined which of these two ovarian function parameters is superior in assessing ovarian reserve with a single test and which test, or combination of tests, will in the future be used in routine infertility evaluations.

Key Words: Anti-müllerian hormone, müllerian inhibiting substance, follicle-stimulating hormone, ovarian reserve testing

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 T.S. has nothing to disclose. D.H.B. has nothing to disclose. A.W. has nothing to disclose. N.G. has nothing to disclose.

 Supported by The Foundation for Reproductive Medicine.

 Presented in part at the 63rd Annual Meeting of the American Society for Reproductive Medicine, October 13–17, 2007, Washington D.C.

PII: S0015-0282(08)00701-2

doi:10.1016/j.fertnstert.2008.03.034

Fertility and Sterility
Volume 91, Issue 6 , Pages 2616-2619, June 2009

Article Tools

* Image Usage & Resolution